Atossa Q3 Loss Narrows to $5.6M as Cash Falls to $20.6M
ATOS sits 26% above its 52-week low of $1.7.
Summary
Atossa posted a Q3 2026 net loss of $5.6 million, or $0.56 per share, narrower than the $8.7 million ($1.01) loss a year earlier, as total operating expenses fell to $5.9 million from $9.3 million. Cash and equivalents dropped to $20.6 million at September 30 from $41.3 million at year-end 2025, leaving a thin runway for a clinical-stage company with no revenue. The quarter's news flow was dominated by the stapled CVR agreement giving holders 25% of net proceeds from a first priority review voucher, capped at $50 million — but no PRV has been awarded and the company says there is no assurance one will be. Near-term value hinges on FDA IND clearance for (Z)-endoxifen in DMD and MAS, expected by early 2027, with Phase 2 trials starting later that year. Karisma follow-up and I-SPY2 data are due at the San Antonio Breast Cancer Symposium in December 2026, and EVANGELINE Phase 2 topline is expected in Q2 2027.
At the time of this announcement, ATOS was trading at $2.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.3M. The 52-week trading range was $1.70 to $14.85. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.